RMI venture fund is currently managed by RMI Partners, a venture capital company focused on breakthrough developments of pharmaceutical products and technologies.
RMI was created in March 2012. Initial funding - $380 million. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government.
The key strategic objective RusnanoMedInvest is to create a Russian-domiciled locus of world-class expertise in venture capital fundraising, deal origination and execution in Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.
RusnanoMedInvest is now evaluating a wide range of life sciences and pharmaceuticals investment opportunities with a view to investing in approximately 20 promising technologies and localizing these technologies in Russia.
Ultimately the goal of these investments and associated localization strategies is to significantly reduce the introduction lead time of new and innovative medicines and medical devices in Russia targeted at delivering significant therapeutic benefits and efficiencies in disease areas that are classified as socially significant complex, poorly treated and widely prevalent diseases in Russia in cases where no domestically sourced, effective treatment methods are available today.
NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.
24 May 2017
23 May 2017